Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abbott Laboratories (ABT) vs Kinder Morgan Inc (KMI) Price & Performance

Abbott LaboratoriesTrade
Kinder Morgan IncTrade

Price performance (Past 24H)

Key statistics

Abbott Laboratories vs Kinder Morgan Inc — how do they compare? Abbott Laboratories trades at $109.3 (market cap $187.95B), while Kinder Morgan Inc trades at $31.46 (market cap $70.10B). The key difference: Abbott Laboratories is far larger — about 2.7× Kinder Morgan Inc's market cap, and Kinder Morgan Inc pays the higher dividend (3.75%). Which is the better fit depends on your goals.

ABTKMI
Market Cap
$187.95B$70.10B
Sector
HealthEnergy
52-Week High
$136.62$34.31
52-Week Low
$82.57$25.84
Enterprise Value
$214.96B$102.15B
Dividend Yield
2.32%3.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abbott Laboratories

Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.

Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.

Kinder Morgan Inc

KMI trades at $31.39, up 1.75% today, with a bearish technical signal but strong fundamentals including consistent earnings beats and a 19.31% net income margin. Recent news highlights a $5 billion Western Gateway Pipeline joint venture with Phillips 66 and HF Sinclair, signaling growth in energy infrastructure.

The outlook is mixed: robust cash flow and dividend sustainability support income investors, but high debt levels and bearish technical indicators pose risks. Analyst consensus is nearly split between Buy and Hold, reflecting cautious optimism amid valuation concerns.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abbott Laboratories

Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Read more on ABT

About Kinder Morgan Inc

Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.

Read more on KMI